Published in J Hematol Oncol on February 06, 2013
Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents. J Hematol Oncol (2014) 1.11
Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol (2013) 1.02
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer (2014) 0.94
Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized. J Hematol Oncol (2016) 0.81
Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway. J Hematol Oncol (2015) 0.80
Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol (2017) 0.75
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood (2006) 3.85
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood (2005) 3.63
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood (2005) 2.58
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood (2009) 2.54
Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol (2009) 2.50
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia (2007) 1.79
Adult acute lymphoblastic leukemia: concepts and strategies. Cancer (2010) 1.78
Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 1.69
Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. J Clin Oncol (2008) 1.65
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia (2007) 1.63
Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol (2007) 1.37
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood (2006) 1.30
Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol (2002) 1.25
Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol (2009) 1.16
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia (2002) 1.16
Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol (2011) 1.11
Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood (1991) 1.08
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. Cancer (2012) 1.06
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica (2007) 0.99
GIMEMA ALL - Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica (2004) 0.93
Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission. Biol Blood Marrow Transplant (2009) 0.92
Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer (2010) 0.89
Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia. Int J Hematol (2010) 0.86
Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood (1996) 0.85
Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol (2006) 0.84
Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant (1998) 0.83
Minimal residual disease in early phase of chemotherapy reflects poor outcome in children with acute lymphoblastic leukemia--a retrospective study by the Children's Cancer and Leukemia Study Group in Japan. Leuk Lymphoma (2002) 0.80
Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. Leuk Lymphoma (2001) 0.79
Chemotherapy or allografting for young adults with high-risk ALL? Blood (2008) 0.77
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood (2005) 6.16
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 5.98
Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell (2007) 5.94
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol (2007) 5.21
Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science (2005) 4.75
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet (2004) 4.45
Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev Cell (2002) 4.37
Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity (2004) 3.84
Hematopoietic stem cells expressing the myeloid lysozyme gene retain long-term, multilineage repopulation potential. Immunity (2003) 3.59
C/EBPbeta is required for 'emergency' granulopoiesis. Nat Immunol (2006) 3.53
Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest (2003) 3.52
Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A (2002) 3.50
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
LTRPC2 Ca2+-permeable channel activated by changes in redox status confers susceptibility to cell death. Mol Cell (2002) 3.36
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood (2005) 3.32
Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol (2010) 3.13
Plasmacytoid dendritic cells activate lymphoid-specific genetic programs irrespective of their cellular origin. Immunity (2004) 3.09
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (2007) 2.92
Myeloid lineage commitment from the hematopoietic stem cell. Immunity (2007) 2.76
Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood (2005) 2.64
Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell (2011) 2.62
The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. Genes Dev (2006) 2.62
Safety of workers at the Fukushima Daiichi nuclear power plant. Lancet (2011) 2.60
Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci U S A (2005) 2.59
Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. Cell Stem Cell (2007) 2.57
Sequential roles of Brg, the ATPase subunit of BAF chromatin remodeling complexes, in thymocyte development. Immunity (2003) 2.56
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell (2005) 2.51
Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell (2002) 2.48
Incidence of small bowel injury induced by low-dose aspirin: a crossover study using capsule endoscopy in healthy volunteers. Digestion (2009) 2.43
Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. Blood (2009) 2.39
The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation. EMBO J (2007) 2.34
Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood (2012) 2.30
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol (2007) 2.29
Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med (2009) 2.26
Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood (2011) 2.24
Clinical factors predictive of spontaneous remission or relapse in cases of autoimmune pancreatitis. Gastrointest Endosc (2007) 2.23
Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J Clin Invest (2002) 2.22
Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood (2006) 2.18
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood (2004) 2.11
Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc Natl Acad Sci U S A (2009) 2.08
GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. Immunity (2003) 2.05
Cyclin A is redundant in fibroblasts but essential in hematopoietic and embryonic stem cells. Cell (2009) 2.05
Gene expression analysis of purified hematopoietic stem cells and committed progenitors. Blood (2003) 2.05
Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol (2009) 2.04
Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum (2008) 1.97
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol (2012) 1.97
Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol (2005) 1.96
Genetic variants in C5 and poor response to eculizumab. N Engl J Med (2014) 1.91
Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis (2005) 1.90
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) (2010) 1.86
Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood (2008) 1.86
Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells. Mol Cell Biol (2003) 1.84
Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol (2002) 1.82
Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet (2005) 1.82
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J (2005) 1.79
Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage. J Exp Med (2008) 1.79
Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med (2010) 1.78
B cell activation regulates exosomal HLA production. Eur J Immunol (2008) 1.78
Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med (2005) 1.76
Characterization of mouse clonogenic megakaryocyte progenitors. Proc Natl Acad Sci U S A (2002) 1.70
Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev (2003) 1.70
Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use? J Gastroenterol (2005) 1.69
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology (2005) 1.66
Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. Blood (2011) 1.65
Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci U S A (2003) 1.64
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell (2010) 1.64
Non-B, non-T neoplasms with lymphoblast morphology: further clarification and classification. Am J Surg Pathol (2003) 1.63
Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Int J Hematol (2007) 1.63
Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol (2012) 1.62
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci U S A (2004) 1.60
Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells (2010) 1.60
Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol (2006) 1.59
SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection. Blood (2002) 1.59
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood (2009) 1.59
Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun (2007) 1.55
Association of Ureaplasma urealyticum (biovar 2) with nongonococcal urethritis. Sex Transm Dis (2004) 1.54
Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res (2004) 1.53
Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment. Acta Haematol (2006) 1.50
Prominent gelatinous bone marrow transformation presenting prior to myelodysplastic syndrome: a case report with review of the literature. Int J Clin Exp Pathol (2013) 1.50